Sandoz acquires infliximab inhibitor treatment from Pfizer
The therapy's treatable conditions include rheumatoid arthritis (RA) and psoriasis so far. The treatment was originally held by Pfizer.
"Infliximab is one of the most important biologic therapy options for people living with severe autoimmune diseases such as rheumatoid arthritis," Richard Francis, global head of Sandoz, said. "We intend to complete the development and registration of PF-06438179 and make it available to patients across Europe as part of our robust portfolio of immunology treatments."
Infliximab is the subject of a current clinical study, which will be continued by Sandoz researchers. The therapy is almost ready to be submitted for regulatory approval to the European Medicines Agency (EMA).
Sandoz's biosimilar medications are currently being used by patients in the U.S., Europe and Japan.
Organizations in this story
Novartis Corporate Communications 230 Park Avenue, 21st Floor NY, NY - 10169